Diabetes

Yes to Autophagy, no to Diabetes: Mechanistic insights into how autophagy may ameliorate Diabetes Mellitus: Acute or intermittent autophagy  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 5/May/2019, 7.37 am
Yes to Autophagy, no to Diabetes: Mechanistic insights into how autophagy may ameliorate Diabetes Mellitus: Acute or intermittent autophagy  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 5/May/2019, 7.37 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Mechanistic insights into how Liraglutide may aid in the treatment of Diabetes: Liraglutide (brand name: Victoza, Saxenda, others), an acylated glucagon-like peptide-1 (GLP-1) agonist used in the treatment of Type II diabetes, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 5/May/2018, 7.09 am
Mechanistic insights into how Liraglutide may aid in the treatment of Diabetes: Liraglutide (brand name: Victoza, Saxenda, others), an acylated glucagon-like peptide-1 (GLP-1) agonist used in the treatment of Type II diabetes, increases GLP1R and Caveolin-1 (CAV-1) expression, promotes glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 5/May/2018, 7.09 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Comprehensive Diabetes Center and Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, the University of Alabama at Birmingham, Birmingham, AL shows…

read more

Mechanistic insights into how Canagliflozin aids in control of body weight, energy homeostasis and TIIDM:  Canagliflozin (brand name: Invokana, Sulisent, Prominad, others), a  drug used in the treatment of type II diabetes, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 5/May/2019, 6.39 am
Mechanistic insights into how Canagliflozin aids in control of body weight, energy homeostasis and TIIDM:  Canagliflozin (brand name: Invokana, Sulisent, Prominad, others), a  drug used in the treatment of type II diabetes, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 5/May/2019, 6.39 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Mechanistic insights into how Farnesoid-X-receptor may ameliorate Diabetes Mellitus: Farnesoid-X-receptor augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene,5/May/2019, 5.50 am
Mechanistic insights into how Farnesoid-X-receptor may ameliorate Diabetes Mellitus: Farnesoid-X-receptor augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene,5/May/2019, 5.50 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Mechanistic insights into how Liraglutide aids in control of body weight, energy homeostasis and TIIDM: Liraglutide (brand name: Victoza, Saxenda and others), a  drug used in the treatment of type II diabetes, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 4/May/2019, 12.27 am
Mechanistic insights into how Liraglutide aids in control of body weight, energy homeostasis and TIIDM: Liraglutide (brand name: Victoza, Saxenda and others), a  drug used in the treatment of type II diabetes, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 4/May/2019, 12.27 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

VEGFA-based therapy for hyperglycemia: VEGFA  increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 3/May/2019, 8.21 pm
VEGFA-based therapy for hyperglycemia: VEGFA  increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 3/May/2019, 8.21 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say:   A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study was…

read more
Start Typing